Hengsai Bio Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
7
Hengsai Bio General Information
Description
Developer of personalized dendritic cell tumor vaccines intended to provide new treatment approaches and strategies for relapsed and refractory tumors. The company's vaccines focuses on on the field of tumor immunotherapy and has been developed to treat relapsed and refractory tumors, chronic viral infections, autoimmune diseases and other diseases that are in urgent need of effective clinical treatments, enabling healthcare professionals to administer treatments and vaccines with safety, efficiency, and convenience in mind.
Contact Information
Corporate Office
- 4th Floor, Building A1, Number 356 Zhengbo Road, Lingang New Area
- China Pilot Free Trade Zone
- Shanghai, 202413
- China
Corporate Office
- 4th Floor, Building A1, Number 356 Zhengbo Road, Lingang New Area
- China Pilot Free Trade Zone
- Shanghai, 202413
- China
Hengsai Bio Timeline
Hengsai Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 30-Dec-2025 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 10-May-2024 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 16-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 27-Nov-2023 | $13.8M | $18.6M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC | 20-Apr-2022 | $4.71M | $4.71M | Completed | Pre-Clinical Trials |
Hengsai Bio Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Tasly Capital | Corporate Venture Capital | Minority | ||
| Zhongshan Xiwan Investment Holding Development | Venture Capital | Minority | ||
| CuiHeng Group | Corporation | Minority | ||
| Zhongshan Financial Investment | Venture Capital | Minority | ||
| Bison Capital Financial Holdings | Venture Capital | Minority |
Hengsai Bio FAQs
-
When was Hengsai Bio founded?
Hengsai Bio was founded in 2018.
-
Where is Hengsai Bio headquartered?
Hengsai Bio is headquartered in Shanghai, China.
-
What industry is Hengsai Bio in?
Hengsai Bio’s primary industry is Drug Discovery.
-
Is Hengsai Bio a private or public company?
Hengsai Bio is a Private company.
-
What is Hengsai Bio’s current revenue?
The current revenue for Hengsai Bio is .
-
How much funding has Hengsai Bio raised over time?
Hengsai Bio has raised $18.6M.
-
Who are Hengsai Bio’s investors?
Tasly Capital, Zhongshan Xiwan Investment Holding Development, CuiHeng Group, Zhongshan Financial Investment, and Bison Capital Financial Holdings are 5 of 7 investors who have invested in Hengsai Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process